Bruker Corporation (BRKR) Financial Ratios
27 years of historical data (1999–2025) · Healthcare · Medical - Devices
EV/EBITDA
↓
22.91
+2% vs avg
5yr avg: 22.49
30Y Low5.3·High95.6
P/FCF
↑
201.19
↑+144% vs avg
5yr avg: 82.36
30Y Low11.2·High180.1
P/B Ratio
↓
3.46
↓-52% vs avg
5yr avg: 7.24
30Y Low1.8·High11.8
ROE
↓
-0.4%
↑-102% vs avg
5yr avg: 18.8%
30Y Low-11%·High34%
Debt/EBITDA
↑
4.48
↑+29% vs avg
5yr avg: 3.47
30Y Low0.6·High6.3
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BRKR Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Bruker Corporation currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 201.2x P/FCF, 144% above the 5-year average of 82.4x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $8.7B | $7.2B | $8.8B | $10.8B | $10.2B | $12.8B | $8.4B | $8.0B | $4.7B | $5.5B | $3.4B |
| Enterprise Value | $10.5B | $8.9B | $10.8B | $11.7B | $10.8B | $13.2B | $8.6B | $8.2B | $4.7B | $5.6B | $3.5B |
| P/E Ratio → | -381.53 | — | 77.13 | 25.34 | 34.35 | 46.36 | 53.07 | 40.45 | 26.11 | 70.04 | 22.29 |
| P/S Ratio | 2.54 | 2.08 | 2.60 | 3.65 | 4.04 | 5.31 | 4.21 | 3.85 | 2.47 | 3.09 | 2.13 |
| P/B Ratio | 3.46 | 2.85 | 4.83 | 7.65 | 9.02 | 11.83 | 8.59 | 8.51 | 5.12 | 7.36 | 4.91 |
| P/FCF | 201.19 | 165.16 | 64.44 | 44.47 | 70.33 | 67.38 | 35.61 | 56.85 | 24.57 | 49.33 | 36.66 |
| P/OCF | 64.96 | 53.33 | 34.87 | 30.89 | 37.21 | 45.43 | 25.19 | 37.40 | 19.52 | 35.36 | 26.26 |
P/E links to full P/E history page with 30-year chart
BRKR EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Bruker Corporation's enterprise value stands at 22.9x EBITDA, roughly in line with its 5-year average of 22.5x. The Healthcare sector median is 14.2x, placing the stock at a 61% premium on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.59 | 3.22 | 3.95 | 4.28 | 5.44 | 4.33 | 3.95 | 2.48 | 3.14 | 2.18 |
| EV / EBITDA | 22.91 | 19.49 | 24.78 | 21.22 | 20.78 | 26.18 | 26.16 | 21.74 | 14.36 | 19.92 | 15.14 |
| EV / EBIT | 44.30 | 108.09 | 42.49 | 20.88 | 25.20 | 32.25 | 35.80 | 27.61 | 17.07 | 23.56 | 16.87 |
| EV / FCF | — | 205.44 | 79.60 | 48.14 | 74.63 | 69.09 | 36.59 | 58.29 | 24.66 | 50.14 | 37.40 |
BRKR Profitability
Margins and return-on-capital ratios measuring operating efficiency
Bruker Corporation earns an operating margin of 6.9%. Operating margins have compressed from 14.7% to 6.9% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -0.4% indicates the company is currently destroying shareholder equity. ROIC of 4.4% represents below-average returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 45.9% | 45.9% | 49.0% | 51.0% | 51.6% | 50.0% | 47.3% | 48.0% | 47.5% | 46.0% | 46.1% |
| Operating Margin | 6.9% | 6.9% | 7.5% | 14.7% | 17.1% | 17.1% | 12.5% | 14.5% | 13.8% | 12.2% | 11.0% |
| Net Profit Margin | -0.3% | -0.3% | 3.4% | 14.4% | 11.7% | 11.5% | 7.9% | 9.5% | 9.5% | 4.5% | 9.5% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -0.4% | -0.4% | 7.0% | 33.6% | 26.8% | 26.9% | 16.5% | 21.3% | 21.7% | 10.9% | 21.3% |
| ROA | -0.1% | -0.1% | 2.2% | 10.9% | 8.2% | 8.3% | 5.4% | 8.0% | 8.8% | 4.2% | 8.7% |
| ROIC | 4.4% | 4.4% | 6.1% | 16.1% | 20.5% | 23.7% | 15.9% | 21.8% | 22.3% | 20.1% | 17.6% |
| ROCE | 5.0% | 5.0% | 6.7% | 15.2% | 16.0% | 16.6% | 11.3% | 16.5% | 17.8% | 15.8% | 14.4% |
BRKR Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Bruker Corporation carries a Debt/EBITDA ratio of 4.5x, which is highly leveraged (39% above the sector average of 3.2x). Net debt stands at $1.7B ($2.0B total debt minus $299M cash). Interest coverage of just 1.4x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.81 | 0.81 | 1.24 | 0.98 | 1.12 | 1.28 | 0.94 | 0.94 | 0.37 | 0.56 | 0.59 |
| Debt / EBITDA | 4.48 | 4.48 | 5.14 | 2.50 | 2.44 | 2.77 | 2.78 | 2.34 | 1.04 | 1.49 | 1.78 |
| Net Debt / Equity | — | 0.69 | 1.14 | 0.63 | 0.55 | 0.30 | 0.24 | 0.22 | 0.02 | 0.12 | 0.10 |
| Net Debt / EBITDA | 3.82 | 3.82 | 4.72 | 1.62 | 1.20 | 0.65 | 0.70 | 0.54 | 0.06 | 0.33 | 0.30 |
| Debt / FCF | — | 40.28 | 15.16 | 3.66 | 4.30 | 1.71 | 0.98 | 1.44 | 0.10 | 0.82 | 0.74 |
| Interest Coverage | 1.36 | 1.36 | 5.32 | 34.18 | 26.71 | 28.52 | 16.68 | 18.52 | 21.84 | 15.30 | 15.74 |
BRKR Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.73x means Bruker Corporation can comfortably meet its short-term obligations, though there is limited excess liquidity. The quick ratio of 0.87x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 1.80x to 1.73x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.73 | 1.73 | 1.60 | 1.80 | 2.31 | 2.63 | 2.43 | 2.78 | 2.18 | 2.59 | 2.42 |
| Quick Ratio | 0.87 | 0.87 | 0.77 | 0.99 | 1.44 | 1.88 | 1.56 | 1.89 | 1.33 | 1.66 | 1.58 |
| Cash Ratio | 0.23 | 0.23 | 0.14 | 0.41 | 0.71 | 1.24 | 0.92 | 1.06 | 0.54 | 0.84 | 0.95 |
| Asset Turnover | — | 0.55 | 0.58 | 0.70 | 0.70 | 0.66 | 0.65 | 0.75 | 0.89 | 0.91 | 0.89 |
| Inventory Turnover | 1.70 | 1.70 | 1.61 | 1.50 | 1.53 | 1.70 | 1.51 | 1.87 | 1.95 | 1.96 | 1.97 |
| Days Sales Outstanding | — | 78.17 | 76.03 | 76.56 | 85.86 | 62.93 | 61.58 | 63.79 | 68.78 | 66.00 | 55.25 |
BRKR Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Bruker Corporation returns 0.4% to shareholders annually — split between a 0.3% dividend yield and 0.1% buyback yield.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.3% | 0.3% | 0.3% | 0.3% | 0.3% | 0.2% | 0.3% | 0.3% | 0.5% | 0.5% | 0.8% |
| Payout Ratio | — | — | 26.7% | 6.9% | 10.0% | 8.7% | 15.6% | 12.7% | 14.0% | 32.3% | 16.8% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 1.3% | 3.9% | 2.9% | 2.2% | 1.9% | 2.5% | 3.8% | 1.4% | 4.5% |
| FCF Yield | 0.5% | 0.6% | 1.6% | 2.2% | 1.4% | 1.5% | 2.8% | 1.8% | 4.1% | 2.0% | 2.7% |
| Buyback Yield | 0.1% | 0.1% | 0.0% | 1.4% | 2.6% | 1.2% | 1.5% | 1.8% | 0.0% | 2.8% | 4.7% |
| Total Shareholder Yield | 0.4% | 0.5% | 0.3% | 1.7% | 2.9% | 1.4% | 1.8% | 2.1% | 0.5% | 3.3% | 5.4% |
| Shares Outstanding | — | $152M | $150M | $147M | $149M | $153M | $155M | $157M | $157M | $159M | $162M |
Peer Comparison
Compare BRKR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BRKRYou | $9B | -381.5 | 22.9 | 201.2 | 45.9% | 6.9% | -0.4% | 4.4% | 4.5 |
 WAT | $23B | 33.0 | 21.8 | 42.9 | 57.8% | 28.2% | 29.3% | 20.3% | 1.3 |
 TRMB | $12B | 28.1 | 16.2 | 87.4 | 68.3% | 16.9% | 7.3% | 6.8% | 1.8 |
 FTV | $19B | 35.1 | 17.5 | 19.2 | 61.0% | 17.7% | 7.0% | 6.0% | 2.6 |
 A | $36B | 27.8 | 21.2 | 31.2 | 52.4% | 21.3% | 20.6% | 13.5% | 1.9 |
 TMO | $173B | 26.2 | 18.7 | 27.4 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 MTD | $23B | 27.1 | 20.4 | 27.3 | 57.5% | 27.8% | — | 40.0% | 1.9 |
 ROP | $34B | 23.3 | 13.8 | 13.6 | 69.2% | 28.3% | 7.9% | 6.1% | 3.0 |
 DHR | $125B | 35.2 | 18.4 | 23.8 | 60.9% | 20.9% | 7.1% | 5.9% | 2.4 |
 ILMN | $25B | 29.7 | 22.7 | 26.4 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 BIO | $8B | 10.1 | 18.1 | 20.4 | 52.0% | 10.5% | 10.8% | 2.6% | 3.2 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 27 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
BRKR — Frequently Asked Questions
Quick answers to the most common questions about buying BRKR stock.
What is Bruker Corporation's P/E ratio?
Bruker Corporation's current P/E ratio is -381.5x. The historical average is 38.5x.
What is Bruker Corporation's EV/EBITDA?
Bruker Corporation's current EV/EBITDA is 22.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 25.0x.
What is Bruker Corporation's ROE?
Bruker Corporation's return on equity (ROE) is -0.4%. The historical average is 12.3%.
Is BRKR stock overvalued?
Based on historical data, Bruker Corporation is trading at a P/E of -381.5x. Compare with industry peers and growth rates for a complete picture.
What is Bruker Corporation's dividend yield?
Bruker Corporation's current dividend yield is 0.26%.
What are Bruker Corporation's profit margins?
Bruker Corporation has 45.9% gross margin and 6.9% operating margin.
How much debt does Bruker Corporation have?
Bruker Corporation's Debt/EBITDA ratio is 4.5x, indicating high leverage. A ratio above 4x may signal elevated financial risk.